Profile of:


Full name: joachim-sieper

Current country: Germany

Membership level: Full

Type of membership: EC

Number of publications: 4

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial (2020)

The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis (2019)

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial (2019)

Axial spondyloarthritis (2017)